Nuvectis Pharma, Inc. (NVCT) vs Zevra Therapeutics, Inc. (ZVRA)

Nuvectis Pharma, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. Nuvectis Pharma, Inc. and Zevra Therapeutics, Inc. are of similar size ($618.0M and $609.9M). Nuvectis Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 10.5×. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Zevra Therapeutics, Inc. leads on 10 and Nuvectis Pharma, Inc. on 1.

Valuation

Metric NVCT ZVRA Biotechnology median
P/E n/m 10.47 8.50
P/S n/m 4.33 9.71
P/B 47.77 2.70 2.13
Price to free cash flow n/m 17.80 20.82
EV/EBITDA n/m 5.79 0.64
EV/Sales n/m 3.43 9.21
Earnings yield (7.09%) 9.55% (33.15%)
Free cash flow yield (4.50%) 5.62% (25.50%)

Profitability

Metric NVCT ZVRA Biotechnology median
Gross margin — 95.46% 65.16%
Operating margin 0.00% 60.54% 0.00%
Net margin 0.00% 42.25% 0.00%
Free cash flow margin 0.00% 24.30% 0.00%
Return on equity (233.30%) 34.33% (56.36%)
Return on assets (122.61%) 20.57% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVCT ZVRA Biotechnology median
Revenue growth (TTM) — 119.40% 6.02%
EPS growth (last fiscal year) (18.92%) 159.21% 30.26%
Revenue growth, 5-year CAGR — 51.62% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVCT ZVRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.68 5.17 4.72
Net debt to EBITDA 1.15 39.03 0.96

Dividend

Metric NVCT ZVRA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NVCT ZVRA Biotechnology median
Market cap 617.95m 609.88m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack